EMA receives application for conditional marketing authorisation of COVID-19 Vaccine Janssen

The CHMP will assess the vaccine under an accelerated timetable aiming to issue an opinion by the middle of March 2021, provided the company’s data on the vaccine’s efficacy, safety and quality are sufficiently comprehensive and robust.

Source:

European Medicines Agency